tbuckley/cabot-search huggingface dataset:
Validation of a cell cycle progression score for 5-year mortality risk in patients with stage I non-small cell lung cancer.
Authors: Takashi Eguchi, Kadota Kyuichi, Brent Evans, Camelia S. Sima, Thaylon Davis, Stephanie A. Hamilton, Kraig Yager, Kathryn A. Kolquist, Joshua Timothy Jones, Anne-Renee Hartman, Prasad S. Adusumili
Journal: Journal of Clinical Oncology (2015)

7522 Background: The aim of this study was to validate a molecular expression signature [cell cycle progression (CCP) score] and a Prognostic Score [(PS) combination of CCP and pathological stage (IA or IB)] that identify stage I non-small cell lung cancer patients with a higher risk of cancer-related death after surgical resection. Methods: Formalin-fixed paraffin-embedded surgical tumor samples from 1200 patients diagnosed with stage I adenocarcinoma who underwent definitive surgical treatment without adjuvant chemotherapy were analyzed for 31 proliferation genes by quantitative RT-PCR. The prognostic discrimination of the CCP score and the PS were assessed by Cox proportional hazards regression using 5-year lung cancer death as primary outcome. Results: In a multivariate model the CCP score was a significant prognostic marker of 5-year lung cancer mortality [hazard ratio (HR) = 1.54 per interquartile range (95% confidence interval = 1.10–2.15; p = 0.0110)]. Other significant variables included age, tumor size, lymphatic invasion, morphology grade and type of surgery. Gender, smoking status, pathological stage, pleural invasion and vascular invasion were not significant. In a separate multivariate model the PS was a significant prognostic marker of 5-year lung cancer mortality [hazard ratio (HR) = 1.76 per interquartile range (95% confidence interval = 1.14–2.72; p = 0.0112)]. Using a previously established threshold (85th percentile) of the PS, there was a significant difference in lung cancer survival between low-risk and high-risk patient groups (p < 0.0001). Conclusions: This study validates both the CCP score and PS as independent prognostic markers of lung cancer death in patients with Stage I lung adenocarcinoma treated with surgery alone. Significantly, in the Stage IB population, CCP and PS provide quantitative risk information above that captured by current NCCN high risk features. Patients with resected stage I lung adenocarcinoma and a high CCP and PS may be candidates for adjuvant therapy to reduce cancer related mortality.
ROLE OF IMPLANTABLE DEFIBRILLATORS IN PRIMARY PREVENTION OF MORTALITY IN NON-ISCHEMIC CARDIOMYOPATHY PATIENTS
Authors: Abhilash Akinapelli, Aashay Patel, Abdulghani Saadi, Muhammad Soubhi Azzouz, Arun Kanmanthareddy, Alok Saurav, Ahmed Aboeata
Journal: Journal of the American College of Cardiology (2017)
PREDICTORS OF 90-DAY READMISSION AND IN HOSPITAL MORTALITY AMONGST PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS: INSIGHTS FROM A NATIONAL DATABASE
Authors: Shilpkumar Arora, Prashant Patel, Harshil Shah, Varun Kumar, Chirag Savani, Kosha Thakore, Sidakpal Panaich, Rajvee Patel, Ambarish Pathak, Apurva Badheka
Journal: Journal of the American College of Cardiology (2017)
VALUE OF AUTOMATED AND SEMI-AUTOMATED MEASUREMENT BY NOVEL THREE-DIMENSIONAL ECHOCARDIOGRAPHY SOFTWARE FOR AORTIC ANNULUS SIZING IN CANDIDATES OF TRANSCATHETER AORTIC VALVE REPLACEMENT: COMPARISON WITH MULTI-DETECTOR COMPUTED TOMOGRAPHY
Authors: Nahoko Kato, Kentaro Shibayama, Yu Fukui, Makio Muraishi, Masahiko Noguchi, Yu Makihara, Hiroshi Okumura, Kotaro Obunai, Mitsuaki Isobe, Hiroyuki Watanabe
Journal: Journal of the American College of Cardiology (2017)
PLATELET REACTIVITY AND OUTCOMES AFTER PCI OF SAPHENOUS VEIN GRAFTS VERSUS NATIVE CORONARY ARTERIES: THE ADAPT-DES STUDY
Authors: Bjorn Redfors, Philippe Genereux, Ajay Kirtane, Bernhard Witzenbichler, Michael Rinaldi, F.J. Neumann, David Metzger, Timothy Henry, David Cox, Peter L. Duffy, Ernest Mazzaferri, Paul Gurbel, Bruce Brodie, Thomas Stuckey, Thomas McAndrew, Jamie Elizabeth Diamond, Xin Huang, Roxana Mehran, Gregg Stone
Journal: Journal of the American College of Cardiology (2017)
Efficacy of Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients with 1 to 3 Prior Lines of Therapy: Updated Analysis of Pollux
Authors: Saad Z Usmani, Meletios A Dimopoulos, Andrew Belch, Darrell White, Lofti Benboubker, Gordon Cook, Merav Leiba, James Morton, P. Joy Ho, Kihyun Kim, Naoki Takezako, Nushmia Z Khokhar, Mary Guckert, Kaida Wu, Xiang Qin, Tineke Casneuf, Christopher Chiu, A. Kate Sasser, Jesús San-Miguel
Journal: Blood (2016)
Bmi-1 Expression Is Useful To Design Therapy and To Predict Prognosis in Patients with Acute Myeloid Leukemia.
Authors: Moniruddin Chowdhury, Keichiro Mihara, Nanae Nakaju, Sachiko Fukumoto-Hidani, Yoshihiro Takihara, Akiro Kimura
Journal: Blood (2005)
KIDNEY FUNCTION, ANGIOTENSIN-CONVERTING-ENZYME INHIBITOR OR ANGIOTENSIN II RECEPTOR BLOCKER USE, AND SURVIVAL FOLLOWING HOSPITALIZATION FOR HEART FAILURE: A COHORT STUDY
Authors: Michael Chiu, Robert J.H. Miller, Bing Li, Stephen Wilton, Merril Knudtson, Jonathan Howlett, Mathew T. James
Journal: Journal of the American College of Cardiology (2017)
Folate-targeted iron oxide nanoparticles loaded with cisplatin for imaging and therapy in head and neck squamous cell carcinoma (HNSCC).
Authors: Hyunseok Kang, Jing Huang, Hui Mao, Zhuo Georgia Chen, Xianghong Peng, Dong Moon Shin
Journal: Journal of Clinical Oncology (2012)

e13110 Background: Cisplatin (DDP) is a widely used anticancer drug but its application has been limited by side effects and drug resistance. We have previously showed that selective delivery of DDP to tumors using novel nanoparticles could significantly enhance antitumor effects with reduced toxicity. As our group has reported that 45% of 105 HNSCC primary tumors were positive for folate receptor (FR) in Head Neck 31:475-81, 2009, we further developed DDP-loaded folate-targeted iron oxide nanoparticle (FA-IO-DDP) for HNSCC imaging and therapy. Methods: HNSCC cell lines were screened for FR expression by Western blot and surface expression was confirmed by FACS. Intracellular platinum (Pt) and Pt-DNA adducts were quantified by ICP-mass spectrometry. MTT assay was used for cytotoxicity test. T2 weighted MRI was used to detect signal changes induced by FA-IO-DDP. Biodistribution of the nanoparticles was studied using nude mice bearing high FR expressing KB3-1 xenograft. Results: Five cell lines expressing surface FR were identified among sixteen cell lines screened. Three cell lines, PCI15B, SQCCY1 and UMSCC11B with high, intermediate, and negative FR expression respectively, were selected for further investigation. FA-IO-DDP showed significantly enhanced cytotoxicity. Intracellular Pt and Pt-DNA adducts were increased in FR-positive PCI15B cells treated with FA-IO-DDP by 4 fold and 3.2 fold, respectively, compared to cells treated with non-targeted IO-DDP. Similar degree of enhanced uptake was observed in SQCCY1 but not in UMSCC11B. A significant change in T2 signal induced by increased internalization of IO in FA-IO-DDP treated PCI15B cells was detected by MRI. In KB3-1 xenograft model, FA-IO-DDP showed 5.4 fold higher accumulation in tumor compared to free DDP. Conclusions: Our study showed that novel FA-IO-DDP targeting FR remarkably enhanced antitumor effects of DDP in FR-positive HNSCC cells by increasing intracellular Pt concentration and Pt-DNA adducts. MRI may be used to monitor DDP delivery by IO nanoparticles in vivo. Ongoing studies are focused on antitumor effect and toxicities of the FA-IO-DDP using nude mice bearing PCI15B, SQCCY1 and UMSCC11B cells.
Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis – A <scp>EUFOREA</scp>‐<scp>ARIA</scp>‐<scp>EPOS</scp>‐<scp>AIRWAYS ICP</scp> statement
Authors: P. W. Hellings, W. J. Fokkens, C. Bachert, C. A. Akdis, T. Bieber, I. Agache, M. Bernal‐Sprekelsen, G. W. Canonica, P. Gevaert, G. Joos, V. Lund, A. Muraro, M. Onerci, T. Zuberbier, B. Pugin, S. F. Seys, J. Bousquet
Journal: Allergy (2017)

Precision medicine (PM) is increasingly recognized as the way forward for optimizing patient care. Introduced in the field of oncology, it is now considered of major interest in other medical domains like allergy and chronic airway diseases, which face an urgent need to improve the level of disease control, enhance patient satisfaction and increase effectiveness of preventive interventions. The combination of personalized care, prediction of treatment success, prevention of disease and patient participation in the elaboration of the treatment plan is expected to substantially improve the therapeutic approach for individuals suffering from chronic disabling conditions. Given the emerging data on the impact of patient stratification on treatment outcomes, European and American regulatory bodies support the principles of PM and its potential advantage over current treatment strategies. The aim of the current document was to propose a consensus on the position and gradual implementation of the principles of PM within existing adult treatment algorithms for allergic rhinitis (AR) and chronic rhinosinusitis (CRS). At the time of diagnosis, prediction of success of the initiated treatment and patient participation in the decision of the treatment plan can be implemented. The second-level approach ideally involves strategies to prevent progression of disease, in addition to prediction of success of therapy, and patient participation in the long-term therapeutic strategy. Endotype-driven treatment is part of a personalized approach and should be positioned at the tertiary level of care, given the efforts needed for its implementation and the high cost of molecular diagnosis and biological treatment.
THE IMPACT OF GLUCAGON LIKE PEPTIDE-1 AGONIST THERAPY ON HEART RATE IN ADVANCED SYSTOLIC HEART FAILURE: AN ANALYSIS FROM THE FUNCTIONAL IMPACT OF GLP-1 FOR HEART FAILURE TREATMENT STUDY
Authors: Amanda R. Vest, Seth N. Meltzer, Jie-Lena Sun, Steven McNulty, Kevin Anstrom, Gordon S. Huggins, Michael S. Kiernan, David DeNofrio, Marvin A. Konstam
Journal: Journal of the American College of Cardiology (2017)
TIMING MATTERS – HYDRATION STRATEGIES TO REDUCE CONTRAST INDUCED NEPHROPATHY AFTER PERIPHERAL VASCULAR INTERVENTIONS: OBSERVATIONS FROM THE BLUE CROSS BLUE SHIELD CARDIOVASCULAR CONSORTIUM (BMC2)
Authors: Thejasvi Thiruvoipati, Fredy El Sakr, Scott Grey, Hitinder Gurm, Paul Grossman
Journal: Journal of the American College of Cardiology (2017)
DNA methylation profile predicts risk of recurrence in tamoxifen-treated, node-negative breast cancer patients
Authors: S. Maier, I. Nimmrich, A. Marx, S. Eppenberger-Castori, F. Jaenicke, A. Paradiso, F. Spyratos, J. Foekens, M. Schmitt, N. Harbeck
Journal: Journal of Clinical Oncology (2004)

525
PROGNOSTIC SIGNIFICANCE OF CO-EXISTING PERSISTENT EDEMA AND HEMORRHAGE AT 6 MONTHS IN SURVIVORS OF ST-ELEVATION MYOCARDIAL INFARCTION
Authors: Jaclyn Carberry, David Carrick, Caroline Haig, Nadeem Ahmed, Vannesa T.Y. May, Margaret McEntegart, Hany Eteiba, M. Mitchell Lindsay, Stuart Hood, Stuart Watkins, Andrew Davie, Ahmad Mahrous, Ify Mordi, Ian Ford, Aleksandra Radjenovic, Keith Oldroyd, Colin Berry
Journal: Journal of the American College of Cardiology (2017)
Oxidative Stress Levels Are Correlated with Disease Progression and Iron Overload in MDS Patients with Excess Blasts
Authors: Naomi Shimizu, Yasuhiro Watanabe, Noriko Ban, Takashi Yamaguchi, Hidekazu Hasunuma, Youichi Iwashita, Hiromitsu Yokota, Chiaki Nakaseko, Hideaki Bujo, Ichiro Tatsuno
Journal: Blood (2016)
Early Achievement of MRD-Negativity in IGHV-Mutated (IGHV-M) Patients Portends Highly Favorable Outcomes after First-Line Treatment of CLL with Fludarabine, Cyclophosphamide and Rituximab (FCR). Serial Monitoring for Minimal Residual Disease (MRD) in Blood after Achieving MRD-Negativity Predicts Subsequent Clinical Relapse
Authors: Philip A Thompson, Paolo Strati, Michael Keating, Susan M. O'Brien, Alessandra Ferrajoli, Jan A Burger, Jeffrey L. Jorgensen, Stefan Faderl, Zeev Estrov, Nitin Jain, Tapan Kadia, Gautam Borthakur, Courtney D. DiNardo, Naval G. Daver, Elias J. Jabbour, William G Wierda
Journal: Blood (2016)
ARTERIAL RESERVE LIMITATIONS IN HEART FAILURE WITH PRESERVED EJECTION FRACTION AND THE BENEFICIAL EFFECTS OF SODIUM NITRITE
Authors: Yogesh N.V. Reddy, Mads Andersen, Masaru Obokata, Katlyn Koepp Borlaug, Vojtech Melenovsky, Thomas Olson, Barry Borlaug
Journal: Journal of the American College of Cardiology (2017)
A Novel Approach to Identify a Putative Leukemia Stem Cell Population in Acute Lymphocytic Leukemia (ALL) and Distinguish Philadelphia Chromosome-Positive ALL from Lymphoid Blast Crisis Chronic Myeloid Leukemia
Authors: Jonathan M. Gerber, Lawrence J. Druhan, David Foureau, Elizabeth Jandrisevits, Amanda Lance, Andrea E. Price, Virginia Thurston, Jing Ai, Michael R. Grunwald, Edward H. Lipford, Belinda R. Avalos
Journal: Blood (2016)
A Phase 1 Study to Assess the Absolute Bioavailability and Safety of An Oral Solution of Decitabine In Subjects with Myelodysplastic Syndromes (MDS),
Authors: Bipin Mistry, Mark M Jones, Peter Kubiak, Guillermo Garcia-Manero, Mark R. Litzow, Ruben A. Mesa, Robert Rifkin, Peter Tarassoff, Jorge E. Cortes
Journal: Blood (2011)
Omacetaxine mepesuccinate in chronic phase chronic myeloid leukemia (CML-CP): A post hoc analysis of myelosuppression.
Authors: Luke Paul Akard, Hagop M. Kantarjian, Franck E. Nicolini, Meir Wetzler, Jeffrey Howard Lipton, Michele Baccarani, Hanna Jean Khoury, Adam Craig, Jorge E. Cortes
Journal: Journal of Clinical Oncology (2013)

7073 Background: Omacetaxine mepesuccinate (OMA) was active in 2 CML trials of patients with T315I Bcr-Abl mutations or failing ≥2 tyrosine kinase inhibitors. Methods: Hematologic events/recovery were pooled from the 2 trials. OMA 1.25 mg/m 2 BID was given in 28-day cycles: ≤14 days induction, ≤7 days maintenance with dose delay/change as needed. Results: Of 108 patients, median exposure was 7.4 mos, with a median 3 cycle delays and 9 days dosing per patient. Of 91 patients receiving ≥2 cycles, 79 (87%) had ≥1 delay (366 delays in 729 cycles), most due to grade ≥3 thrombocytopenia. Median delay was longest early—peaking at 25 days in cycle 3. Predefined hematologic nadirs (see Table) were reached mostly in initial cycles and less after dose adjustments; 80 patients received blood products, 10 antibiotics. Most common lab grade 3/4 hematologic toxicities were thrombocytopenia (85%), neutropenia (81%), and anemia (62%). Grade 3/4 adverse events included 12 infections (6 treatment related, including 1 pneumonia, 1 sepsis) and 7 hemorrhages (1 related conjunctival, 1 postprocedural, 2 cerebral, 3 gastrointestinal [1 related]); 38 events were fatal (related: 1 pancytopenia, 2 sepsis, 2 unknown). There were 11 hematologic hospitalizations. Conclusions: In heavily pretreated CML-CP, myelosuppression was most common after initial OMA cycles, improved with dose adjustments, and rarely led to severe outcomes. Support: Teva BPP R&amp;D, Inc. Clinical trial information: NCT00375219, NCT00462943. [Table: see text]
Sema3E–Plexin D1 signaling drives human cancer cell invasiveness and metastatic spreading in mice
Authors: Andrea Casazza, Veronica Finisguerra, Lorena Capparuccia, Andrea Camperi, Jakub M. Swiercz, Sabrina Rizzolio, Charlotte Rolny, Claus Christensen, Andrea Bertotti, Ivana Sarotto, Mauro Risio, Livio Trusolino, Jurgen Weitz, Martin Schneider, Massimiliano Mazzone, Paolo M. Comoglio, Luca Tamagnone
Journal: Journal of Clinical Investigation (2011)
Bortezomib, Ascorbic Acid and Melphalan (BAM) Therapy for Patients (pts) with Newly Diagnosed Multiple Myeloma (MM): An Effective and Well-Tolerated Frontline Regimen.
Authors: James R. Berenson, Ori Yellin, Donald Woytowitz, Marshall S. Flam, Alan Cartmell, Ravi Patel, Herb Duvivier, Youram Nassir, Regina A. Swift
Journal: Blood (2007)
High gene copy number of epidermal growth factor receptor by fluorescence in situ hybridization is frequent in head and neck squamous cell carcinomas and associates with worse recurrence-free survival
Authors: C. H. Chung, K. Ely, J. Carter, L. McGavran, M. Varella-Garcia, L. Nanney, Y. Yi, R. J. Slebos, W. Yarbrough, F. R. Hirsch
Journal: Journal of Clinical Oncology (2006)

5502 Background: Epidermal growth factor receptor (EGFR) is expressed in 90–95% of head and neck squamous cell carcinoma (HNSCC). High EGFR gene copy number and activating mutations correlate with response and survival in lung cancer upon the treatment with EGFR tyrosine kinase inhibitors, but such findings have not been reported for HNSCC. A better understanding of the EGFR pathway may improve the use of EGFR inhibitors and provide a rationale for combination therapy. Methods: Tumor samples were obtained from 47 patients and analyzed for increased EGFR copy numbers by fluorescence in situ hybridization (FISH) (Vysis/Abbot) (N = 47), by immunohistochemistry (IHC) using antibodies against EGFR, phospho-EGFR (Tyr1173) and phospho-AKT (Ser473) (N = 31), for activating mutations in EGFR exons 18, 19 and 21 (N = 29), and for gene expression using Affymetrix Human 133U Plus 2.0 GeneChip (N = 18). Results from these assessments were tested for associations with patient characteristics and clinical endpoints. Univariate analysis was performed to test for differences in recurrence-free survival (RFS) and overall survival. Results: Twenty-six (63%) of 41 samples with FISH result demonstrated EGFR high polysomy and/or gene amplification (FISH+). The FISH(+) group did not differ from the FISH(−) group with regard to age, sex, race, tumor grade and site, disease stage, total EGFR, phospho-EGFR, or phospho-AKT, although the total EGFR protein score was close to significance (p = 0.10, Chi2-test for trend). The FISH(+) were associated with worse RFS, although this association did not reach significance (p = 0.057, Wilcoxon test). No activating EGFR point mutations were found. Using the FISH results as a supervising parameter, microarray data was interrogated and expression of genes involved in wnt signalling, cell motility, G-protein regulation and epithelial-mesenchymal transition pathways were found to be enhanced in the FISH(+) group (FDR &lt;25%). Conclusions: High gene copy number of EGFR by FISH is frequent in HNSCC and may be a poor prognosticator. This data suggests that FISH(+) may be a marker of clinical benefit upon EGFR inhibition in HNSCC and further investigation is indicated. [Table: see text]
HIGH-SENSITIVITY CARDIAC TROPONIN I AND THE DIAGNOSIS OF OBSTRUCTIVE CORONARY ARTERY DISEASE IN PATIENTS WITH SUSPECTED STABLE ANGINA
Authors: Philip D. Adamson, Amanda Hunter, Anoop Shah, David McAllister, Tania Pawade, Michelle Williams, Edwin Van Beek, Nicholas Mills, David Newby
Journal: Journal of the American College of Cardiology (2017)
PERIPROCEDURAL BLOOD TRANSFUSIONS IN PATIENTS UNDERGOING TRANSCATHETER AORTIC VALVE REPLACEMENT
Authors: Konstantinos V. Voudris, Richard B. Devereux, Dmitriy Feldman, Robert Minutello, Luke Kim, Harsimran Singh, Geoffrey Bergman, Arash Salemi, Shing-Chiu Wong
Journal: Journal of the American College of Cardiology (2017)
Functional assessment of performance status in patients with myelofibrosis (MF): Utility and feasibility of the 6-minute walk test (6MWT)
Authors: R. A. Mesa, H. Kantarjian, A. Tefferi, A. Cheville, A. Pardanani, R. Levy, S. Erickson-Viitanen, D. Thomas, J. Cortes, G. Borthakur, S. Verstovsek
Journal: Journal of Clinical Oncology (2009)

7083 Background: Patients with Myelofibrosis (MF) suffer from significant fatigue, constitutional symptoms and splenomegaly (Mesa et. al. Cancer 2007) not improved by current therapy. The 6MWT measures functional status in cardio-pulmonary clinical trials. We undertook a prospective feasibility study of the 6MWT in MF patients for use in therapeutic clinical trials. Methods: MF patients (able to walk, normal vitals, not on a JAK2 inhibitor) were eligible. Baseline features and the MF symptom assessment form (MFSAF: Mesa et. al. Blood 2008) was administered. The 6MWT was administered in standardized fashion (American Thoracic Society: observed laps of a 30 - 35 meter long course, indoors, level, without encouragement), and then repeated for further validation. Results: Safety of the 6MWT: Fifty five MF patients were enrolled with only 2 patients (3%) stopping the 6MWT early secondary to fatigue. There were no adverse events attributable to undergoing the 6MWT in test subjects. Results of the 6MWT: Current results of our ongoing study demonstrate compared to age matched healthy volunteer controls, males with MF walk approximately 90 meters less and females with MF walk approximately 60 meters less (Table). Correlation of 6MWT Results to Patient Reported Symptoms (MFSAF): Results from the MFSAF demonstrated the fatigue (as assessed by the brief fatigue inventory (Medoza et. al. Cancer 1999) embedded in the MFSAF) showed patients with a higher BFI (i.e., more fatigued) had more impairment in the 6MWT than those with low BFI scores. Symptomatic burden as assessed by the MFSAF were typical for MF, correlation of individual symptom severity with 6MWT will require a larger trial for adequate power. Conclusions: The 6MWT can be safely performed in un-selected MF patients, and demonstrates a functional deficit compared to published controls. Validation of the ability of the 6MWT to measure functional improvements in MF patients as a response to novel therapy trials is planned. [Table: see text] No significant financial relationships to disclose.
INCREMENTAL PROGNOSTIC UTILITY OF LATE GADOLINIUM ENHANCEMENT IN HYPERTROPHIC CARDIOMYOPATHY
Authors: Amgad G. Mentias, Pejman Raeisi-Giglou, Ke Feng, Zoran Popovic, Nicholas Smedira, Maran Thamilarasan, Scott Flamm, Harry Lever, Milind Desai
Journal: Journal of the American College of Cardiology (2017)